Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Comprehensive Loss

v3.25.1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 4,161,907 5,442,886
Research and Development Expenses 3,441,010 7,867,795
Stock Based Compensation 1,057,271 3,049,537
Series F Warrant Issuance Expenses 762,834
Series F-1 Warrant Issuance Expenses 539,097
Series G Warrant Issuance Expenses 969,505
Loss from Operations (10,168,790) (17,123,052)
Other (Income) Expenses    
Interest and Dividend Income (351,809) (455,570)
Gain on Sales of Marketable Securities (976) (416)
Unrealized Gain on Marketable Securities (671) (514)
Change in fair value of Derivatives Liabilities 388,000 (3,088,800)
Change in fair value of Warrant Liabilities 4,410,000 (9,756,000)
Loss on issuance of Series F-1 Convertible Preferred Stock 3,737,000
Loss on issuance of Series G Convertible Preferred Stock 5,109,000
Casualty Loss/(Gain) (100,000) 178,198
Total Other (Income) Expenses 13,190,544 (13,123,102)
Loss Before Income Tax (23,359,334) (3,999,950)
Income Tax Benefit
Net Loss (23,359,334) (3,999,950)
Preferred Stock Dividends 3,801,885 4,218,213
Net Loss Attributable to Common Stockholders $ (27,161,219) $ (8,218,163)
Basic net loss per common share $ (11.15) $ (5.33)
Diluted net loss per common share $ (11.15) $ (5.33)
Weighted average basic common stock outstanding 2,437,000 1,542,453
Weighted average diluted common stock outstanding 2,437,000 1,542,453